Vanda Strikes Out at the Supreme Court
April 22, 2024, 3:57 PM
Two weeks ago we discussed Vanda Pharmaceuticals’ ambitious cert petition asking the Supreme Court to discontinue the “reasonable expectation of success” standard for patent obviousness that for decades has been a mainstay of patent law.
Vanda argued that the Court should instead adopt a “predictable results” standard, which would have made patents more difficult to challenge and thereby significantly impacted the pharma and biologics industries. Unsurprisingly, the Court today denied Vanda’s petition, leaving the obviousness standard unchanged.

To subscribe to our publications, click here.
Tags
News & Insights
News & Insights
National Bar Association 100th Annual Convention and Exhibits
Sponsorship
Antitrust
Keeping Pace: Updates in Cartel Enforcement
Webinar
Antitrust
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
Webinar
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
SABA North America Annual Conference 2025
Speaking Engagement
Antitrust
Axinn Recognized by Legal 500 2025 U.S. Guide for Excellence in Antitrust and Litigation
Awards & Recognitions
Axinn Earns Band 1 Recognition in Multiple Categories in 2025 Chambers USA Guide
Awards & Recognitions
Antitrust
United States: Class Actions
Byline Articles
Litigation & Trials
Antitrust 101: Criminal Antitrust Enforcement in U.S. v. US Gypsum Co., 438 US 422 (1978)
Podcast